Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, comments on the success of this year’s ISAL XVIII meeting, and further highlights some of the exciting topics that were covered, including basic biology, novel prognostic scores, and measurable residual disease (MRD) assessment. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.